Multiple endocrine neoplasia type 1 (MEN1): Not only inherited endocrine tumors

Genetics in Medicine

Volumn 11, Issue 12, 2009, Pages 825-835

  Falchetti, Alberto ^a   Marini, Francesca ^a   Luzi, Ettore ^a   Giusti, Francesca ^a   Cavalli, Loredana ^a   Cavalli, Tiziana ^a   Brandi, Maria Luisa ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Familial endocrine cancer syndrome; MEN1; Menin; Neuroendocrine tumors

Indexed keywords

PROTEIN MEN1; TUMOR PROTEIN; UNCLASSIFIED DRUG;

CANCER GROWTH; CANCER RISK; CARCINOID; CENTRAL NERVOUS SYSTEM TUMOR; CHROMOSOME LOSS; CLINICAL FEATURE; ENDOCRINE TUMOR; GASTRINOMA; GENE MUTATION; GENETIC VARIABILITY; HUMAN; HYPOPHYSIS TUMOR; INSULINOMA; LEIOMYOMA; MULTIPLE ENDOCRINE NEOPLASIA; PARATHYROID TUMOR; PHENOTYPIC VARIATION; PREVALENCE; REVIEW; SKIN TUMOR;

GASTRINOMA; GENOTYPE; HUMANS; INSULINOMA; MULTIPLE ENDOCRINE NEOPLASIA TYPE 1; MUTATION; PARATHYROID NEOPLASMS; PHENOTYPE; PITUITARY NEOPLASMS; PROTO-ONCOGENE PROTEINS;

EID: 73849148553     PISSN: 10983600     EISSN: None     Source Type: Journal    
DOI: 10.1097/GIM.0b013e3181be5c97     Document Type: Review

References (150)

1. Erdheim J. Zur normalen und pathologischen histologie der glandula thyroidea, parathyroidea, und hypophysis. Beitr Pathol Anat 1903;33:158-236.
2. Cushing H, Davidoff LM. Studies in acromegaly V. The pathological finding in four autopsied cases of acromegaly with a discussion of their significance. Monograph, New York, NY: Rockefeller Institute for Medical Research; 1927:22.
3. Underdahl LO, Woolner LB, Black BM. Multiple endocrine adenomas: report of eight cases in which the parathyroids, pituitary and pancreatic islets were involved. J Clin Endocrinol Metab 1953;13:20-25.
4. Wermer P. Genetic aspects of adenomatosis of endocrine glands. Am J Med 1954;16:363.
5. Yalow RS. Radioimmunoassay: a probe for the fine structure of biologic systems. Science 1978;200:1236-1245.
6. Malarkey WB. Prolactin and the diagnosis of pituitary tumors. Annu Rev Med 1979;30:249-258.
7. Nussbaum SR, Potts JT Jr. Immunoassays for parathyroid hormone 1-84 in the diagnosis of hyperparathyroidism. J Bone Miner Res 1991;6:S43-S50.
8. Albright F, Ellsworth R, Loriaux DL eds. Uncharted Seas. Portland, OR: Kalmia Press; 1990.
9. Bevan JS, Webster J, Burke W, Scanlon MF. Dopamine agonists and pituitary tumor shrinkage. Endocr Rev 1992;13:220-240.
10. Schmid JR, Labhart A, Rossier PH. Relationship of multiple endocrine adenomas to the syndrome of ulcerogenic islet cell adenomas (Zollinger-Ellison). Occurrence of both syndromes in one family. Am J Med 1961;31:343-348.
11. Gagel RF, Marx SJ. Multiple endocrine neoplasia. In: Larsen PR, Kronen-berg H, Melmed S, Polonsky K, editors. Williams textbook of endocrinology, 11th ed. Orlando, FL: WB Saunders & Company, 2007.
12. Brandi ML, Bordi C, Tonelli F, et al. Multiple endocrine neoplasia type 1. In: Bilezikian JP, Raisz GA, Rodan LG, editors. Principles of bone biology, 3rd ed. San Diego, CA: Academic Press, 2008:1345-1374. Chapter 62.
13. Falchetti A, Marini F, Brandi ML. Multiple endocrine neoplasia type 1. In: GeneReviews at GeneTests: Medical Genetics Information Resource [database online]. Copyright, University of Washington, Seattle, 1997-2005. Available at: http://www.genetests.org. Accessed August 2005.
14. Marx SJ. Multiple endocrine neoplasia type 1. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The metabolic and molecular bases of inherited disease, 8th ed. New York: McGraw-Hill, 2001.
15. Sato M, Miyauchi A, Namihira H, et al. A newly recognized germline mutation of MEN1 gene identified in a patient with parathyroid adenoma and carcinoma. Endocrine 2000;12:223-226.
16. Dionisi S, Minisola S, Pepe J, et al. Concurrent parathyroid adenomas and carcinoma in the setting of multiple endocrine neoplasia type 1: presenta-tion as hypercalcemic crisis. Mayo Clin Proc 2002;77:866-869.
17. Agha A, Carpenter R, Bhattacharya S, Edmonson SJ, Carlsen E, Monson JP. Parathyroid carcinoma in multiple endocrine neoplasia type 1 (MEN1) syndrome: two case reports of an unrecognised entity. J Endocrinol Invest 2007;30:145-149.
18. Verges B, Boureille F, Goudet P, et al. Pituitary disease in MEN type 1 (MEN1): data from the France-Belgium MEN1 multicenter study. J Clin Endocrinol Metab 2002;87:457-465.
19. Al Brahim NY, Rambaldini G, Ezzat S, Asa SL. Complex endocrinopathies in MEN-1: diagnostic dilemmas in endocrine oncology. Endocr Pathol 2007;18:37-41.
20. Trouillas J, Labat-Moleur F, Sturm N, et al. Pituitary tumors and hyper-plasia in multiple endocrine neoplasia type 1 syndrome (MEN1): a case-control study in a series of 77 patients versus 2509 non-MEN1 patients. Am J Surg Pathol 2008;32:534-543.
21. Farid NR, Buehler S, Russell NA, Maroun FB, Allerdice P, Smyth HS. Prolactinomas in familial multiple endocrine neoplasia syndrome type I. Relationship to HLA and carcinoid tumors. Am J Med 1980;69:874-880.
22. Rix M, Hertel NT, Nielsen FC, et al. Cushing's disease in childhood as the first manifestation of multiple endocrine neoplasia syndrome type 1. Eur J Endocrinol 2004;151:709-715.
23. Matsuzaki LN, Canto-Costa MH, Hauache OM. Cushing's disease as the first clinical manifestation of multiple endocrine neoplasia type 1 (MEN1) associated with an R460X mutation of the MEN1 gene. Clin Endocrinol (Oxf) 2004;60:142-143.
24. Stratakis CA, Schussheim DH, Freedman SM, et al. Pituitary macroad-enoma in a 5-year-old: an early expression of multiple endocrine neoplasia type 1. J Clin Endocrinol Metab 2000;85:4776-4780.
25. Yoshimoto K, Saito S. [Clinical characteristics in multiple endocrine neo-plasia type 1 in Japan: a review of 106 patients]. Nippon Naibunpi Gakkai Zasshi 1991;67:764-774 (in Japanese).
26. Carty SE, Helm AK, Amico JA, et al. The variable penetrance and spectrum of manifestations of multiple endocrine neoplasia type 1. Surgery 1998;124:1106-1114.
27. Gordon MV, Varma D, McLean CA, Bittar RG, Burgess JR, Topliss DJ. Metastatic prolactinoma presenting as a cervical spinal cord tumour in multiple endocrine neoplasia type one (MEN-1) Clin Endocrinol (Oxf) 2007;66:150-152.
28. Kloppel G, Perren A, Heitz PU. The gastroenteropancreatic neuroendocrine cell system and its tumors: the WHO classification. Ann NY Acad Sci 2004;1014:13-1027.
29. Gibril F, Schumann M, Pace A, Jensen RT. Multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome: a prospective study of 107 cases and comparison with 1009 cases from the literature. Medicine (Baltimore) 2004;83:43-83.
30. Hao W, Skarulis MC, Simonds WF, et al. Multiple endocrine neoplasia type 1 variant with frequent prolactinoma and rare gastrinoma. J Clin Endocrinol Metab 2004;89:3776-3784.
31. Hoffmann KM, Furukawa M, Jensen RT. Duodenal neuroendocrine tumors: classification, functional syndromes, diagnosis and medical treatment. Best Pract Res Clin Gastroenterol 2005;19:675-697.
32. Anlauf M, Perren A, Meyer CL, et al. Precursor lesions in patients with multiple endocrine neoplasia type 1-associated duodenal gastrinomas. Gas-troenterology 2005;128:1187-1198.
33. Anlauf M, Perren A, Klöppel G. Endocrine precursor lesions and microad-enomas of the duodenum and pancreas with and without MEN1: criteria, molecular concepts and clinical significance. Pathobiology 2007;74:279-284.
34. Anlauf M, Bauersfeld J, Raffel A, et al. Insulinomatosis: a multicentric insulinoma disease that frequently causes early recurrent hyperinsulinemic hypoglycemia. Am J Surg Pathol 2009;33:339-346.
35. Anlauf M, Perren A, Henopp T, et al. Allelic deletion of the MEN1 gene in duodenal gastrin and somatostatin cell neoplasms and their precursor lesions. Gut 2007;56:637-644.
36. Fendrich V, Langer P, Waldmann J, Bartsch DK, Rothmund M. Management of sporadic and multiple endocrine neoplasia type 1 gastrinomas. Br J Surg 2007;94:1331-1341. (Pubitemid 350144380)
37. Marx SJ, Agarwal SK, Kester MB, et al. Multiple endocrine neoplasia type 1: clinical and genetic features of the hereditary endocrine neoplasias. Recent Prog Horm Res 1999;54:397-438.
38. Grama D, Skogseid B, Wilander E, et al. Pancreatic tumors in multiple endocrine neoplasia type 1: clinical presentation and surgical treatment. World J Surg 1992;16:611-618.
39. Mignon M, Ruszniewski P, Podevin P, et al. Current approach to the management of gastrinoma and insulinoma in adults with multiple endocrine neoplasia type I. World J Surg 1993;17:489-497.
40. Butte JM, Montero PH, Solar A, et al. Cervical metastases of glucagonoma in a patient with multiple endocrine neoplasia type 1: report of a case. Surg Today 2008;38:1137-1143.
41. Thomas-Marques L, Murat A, Delemer B, et al. Prospective endoscopic ultrasonographic evaluation of the frequency of nonfunctioning pancreati-coduodenal endocrine tumors in patients with multiple endocrine neoplasia type 1. Am J Gastroenterol 2006;101:266-273.
42. Triponez F, Dosseh D, Goudet P, et al. Epidemiology data on 108 MEN 1 patients from the GTE with isolated nonfunctioning tumors of the pancreas. Ann Surg 2006;243:265-272.
43. Sakurai A, Katai M, Yamashita K, Mori J, Fukushima Y, Hashizume K. Long-term follow-up of patients with multiple endocrine neoplasia type 1. Endocr J 2007;54:295-302.
44. Boix E, Pico A, Pinedo R, Aranda I, Kovacs K. Ectopic growth hormone-releasing hormone secretion by thymic carcinoid tumour. Clin Endocrinol (Oxf) 2002;57:131-134.
45. Takagi J, Otake K, Morishita M, et al. Multiple endocrine neoplasia type I and Cushing's syndrome due to an aggressive ACTH producing thymic carcinoid. Intern Med 2006;45:81-86.
46. Yano M, Fukai I, Kobayashi Y, et al. ACTH-secreting thymic carcinoid associated with multiple endocrine neoplasia type 1. Ann Thorac Surg 2006;81:366-368.
47. Schnirer II, Yao JC, Ajani JA. Carcinoid\-a comprehensive review. Acta Oncol 2003;42:672-692.
48. Gibril F, Chen YJ, Schrump DS, et al. Prospective study of thymic carcinoids in patients with multiple endocrine neoplasia type 1. J Clin Endocrinol Metab 2003;88:1066-1081. (Pubitemid 36337758)
49. Teh BT, McArdle J, Chan SP, et al. Clinicopathologic studies of thymic carcinoids in multiple endocrine neoplasia type 1. Medicine (Baltimore) 1997;76:21-29.
50. Ferolla P, Falchetti A, Filosso P, et al. Thymic Neuroendocrine Carcinoma (Carcinoid) in MEN1 Syndrome: the Italian series. J Clin Endocrinol Metab 2005;90:2603-2609.
51. Goudet P, Murat A, Cardot-Bauters C, et al. Thymic neuroendocrine tumors in multiple endocrine neoplasia type 1: a comparative study on 21 cases among a series of 761 MEN1 from the GTE (Groupe des Tumeurs Endocrines). World J Surg 2009;33:1197-1207.
52. Tanabe M, Akatsuka K, Umeda S, et al. Metastasis of carcinoid to the arch of the axis in a multiple endocrine neoplasia patient: a case report. Spine J 2008;8:841-844.
53. Sachithanandan N, Harle RA, Burgess JR. Bronchopulmonary carcinoid in multiple endocrine neoplasia type 1. Cancer 2005;103:509-515.
54. Benya RV, Metz DC, Hijazi YJ, Fishbeyn VA, Pisegna JR, Jensen RT. Fine needle aspiration cytology of submucosal nodules in patients with Zollinger-Ellison syndrome. Am J Gastroenterol 1993;88:258-265.
55. Bordi C, D'Adda T, Azzoni C, Ferraro G. Pathogenesis of ECL cell tumors in humans. Yale J Biol Med 1998;71:273-284.
56. Gibril F, Reynolds JC, Lubensky IA, et al. Ability of somatostatin receptor scintigraphy to identify patients with gastric carcinoids: a prospective study. J Nucl Med 2000;41:1646-1656.
57. Beckers A, Abs R, Willems PJ, et al. Aldosterone-secreting adrenal adenoma as part of multiple endocrine neoplasia type 1 (MEN1): loss of heterozygosity for polymorphic chromosome 11 deoxyribonucleic acid markers, including the MEN1 locus. J Clin Endocrinol Metab 1992;75:564-570.
58. Skogseid B, Larsson C, Lindgren PG, et al. Clinical and genetic features of adrenocortical lesions in multiple endocrine neoplasia type 1. J Clin En-docrinol Metab 1992;75:76-81.
59. Honda M, Tsukada T, Horiuchi T, et al. Primary hyperparathyroidism associated with aldosterone-producing adrenocortical adenoma and breast cancer: relation to MEN1 gene. Intern Med 2004;43:310-314.
60. Skogseid B, Rastad J, Gobl A, et al. Adrenal lesion in multiple endocrine neoplasia type 1. Surgery 1995;118:1077-1082.
61. Waldmann J, Fendrich V, Habbe N, et al. Screening of patients with multiple endocrine neoplasia type 1 (MEN-1): a critical analysis of its value. World J Surg 2009;33:1208-1218.
62. Darling TN, Skarulis MC, Steinberg SM, Marx SJ, Spiegel AM, Turner M. Multiple facial angiofibromas and collagenomas in patients with multiple endocrine neoplasia type 1. Arch Dermatol 1997;133:853-857.
63. Asgharian B, Turner ML, Gibril F, Entsuah LK, Serrano J, Jensen RT. Cutaneous tumors in patients with multiple endocrine neoplasm type 1 (MEN1) and gastrinomas: prospective study of frequency and development of criteria with high sensitivity and specificity for MEN1. J Clin Endocrinol Metab 2004;89:5328-5336.
64. Xia Y, Darling TN. Rapidly growing collagenomas in multiple endocrine neoplasia type I. J Am Acad Dermatol 2007;56:877-880.
65. Kato H, Uchimura I, Morohoshi M, et al. Multiple endocrine neoplasia type 1 associated with spinal ependymoma. Intern Med 1996;35:285-289.
66. McKeeby JL, Li X, Zhuang Z, et al. Multiple leiomyomas of the esophagus, lung, and uterus in multiple endocrine neoplasia type 1. Am J Pathol 2001;159:1121-1127.
67. Ikota H, Tanimoto A, Komatsu H, Ozawa Y, Matsushita H. Ureteral leiomyoma causing hydronephrosis in Type 1 multiple endocrine neopla-sia. Pathol Int 2004;54:457-459.
68. Larsson C, Skogseid B, Oberg K, Nakamura Y, Nordenskjöld M. Multiple endocrine neoplasia type 1 gene maps to chromosome 11 and is lost in insulinoma. Nature 1988;332:85-87.
69. Friedman E, Sakaguchi K, Bale AE, et al. Clonality of parathyroid tumors in familial multiple endocrine neoplasia type 1. N Engl J Med 1989;321: 213-218.
70. Emmert-Buck MR, Lubensky IA, Dong Q, et al. Localization of the multiple endocrine neoplasia type I (MEN1) gene based on tumor loss of heterozygosity analysis. Cancer Res 1997;57:1855-1858.
71. Knudson AG. Antioncogenes and human cancer. Proc Natl Acad Sci USA 1993;90:10914-10921.
72. Chandrasekharappa SC, Guru SC, Manickam P, et al. Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science 1997;276:404-407.
73. Lemmens I, Van de Ven WJ, Kas K, et al. Identification of the multiple endocrine neoplasia type 1 (MEN1) gene. The European Consortium on MEN1. Hum Mol Genet 1997;6:1177-1183. (Pubitemid 27308405)
74. Lemos MC, Thakker RV. Multiple endocrine neoplasia type 1 (MEN1): analysis of 1336 mutations reported in the first decade following identification of the gene. Hum Mutat 2008;29:22-32.
75. Agarwal SK, Kester MB, Debelenko LV, et al. Germline mutations of the MEN1 gene in familial multiple endocrine neoplasia type 1 and related states. Hum Mol Genet 1997;6:1169-1175.
76. Heppner C, Kester MB, Agarwal SK, et al. Somatic mutation of the MEN1 gene in parathyroid tumours. Nat Genet 1997;16:375-378.
77. Bassett JH, Forbes SA, Pannett AA, et al. Characterization of mutations in patients with multiple endocrine neoplasia type 1. Am J Hum Genet 1998;62:232-244.
78. Carling T, Correa P, Hessman O, et al. Parathyroid MEN1 gene mutations in relation to clinical characteristics of nonfamilial primary hyperparathyroidism. J Clin Endocrinol Metab 1998;83:2960-2963.
79. Farnebo F, Teh BT, Kytola S, et al. Alterations of the MEN1 gene in sporadic parathyroid tumors. J Clin Endocrinol Metab 1998;83:2627-2630.
80. Giraud S, Zhang CX, Serova-Sinilnikova O, et al. Germ-line mutation analysis in patients with multiple endocrine neoplasia type 1 and related disorders. Am J Hum Genet 1998;63:455-467.
81. Sato M, Matsubara S, Miyauchi A, et al. Identification of five novel germline mutations of the MEN1 gene in Japanese multiple endocrine neoplasia type 1 (MEN1) families. J Med Genet 1998;35:915-919. (Pubitemid 28486619)
82. Teh BT, Kytola S, Farnebo F, et al. Mutation analysis of the MEN1 gene in multiple endocrine neoplasia type 1, familial acromegaly and familial isolated hyperparathyroidism. J Clin Endocrinol Metab 1998;83:2621-2626.
83. Vortmeyer AO, Boni R, Pak E, Pack S, Zhuang Z. Multiple endocrine neoplasia 1 gene alterations in MEN1-associated and sporadic lipomas. J Natl Cancer Inst 1998;90:398-399.
84. Cebrian A, Herrera-Pombo JL, Díez JJ, et al. Genetic and clinical analysis in 10 Spanish patients with multiple endocrine neoplasia type 1. Eur J Hum Genet 1999;7:585-589.
85. Morelli A, Falchetti A, Martineti V, et al. MEN1 gene mutation analysis in Italian patients with multiple endocrine neoplasia type 1. Eur J Endocrinol 2000;142:131-137.
86. Tahara H, Imanishi Y, Yamada T, et al. Rare somatic inactivation of the multiple endocrine neoplasia type 1 gene in secondary hyperparathyroidism of uremia. J Clin Endocrinol Metab 2000;85:4113-4117.
87. Guo SS, Sawicki MP. Molecular and genetic mechanisms of tumorigenesis in multiple endocrine neoplasia type-1. Mol Endocrinol 2001;15:1653-1664.
88. Pannett AA, Thakker RV. Somatic mutations in MEN type 1 tumors, consistent with the Knudson "two-hit" hypothesis. J Clin Endocrinol Metab 2001;86:4371-4374.
89. Sato M, Matsubara S, Murao K, Ishida T, Takahara J. Multiple endocrine neoplasia type 1: usefulness of genetic tests in atypical cases. Intern Med 2001;40:461-462.
90. Turner JJ, Leotlela PD, Pannett AA, et al. Frequent occurrence of an intron 4 mutation in multiple endocrine neoplasia type 1. J Clin Endocrinol Metab 2002;87:2688-2693.
91. Wautot V, Vercherat C, Lespinasse J, et al. Germline mutation profile of MEN1 in multiple endocrine neoplasia type 1: search for correlation between phenotype and the functional domains of the MEN1 protein. Hum Mutat 2002;20:35-47.
92. Park JH, Kim IJ, Kang HC, et al. Germline mutations of the MEN1 gene in Korean families with multiple endocrine neoplasia type 1 (MEN1) or MEN1-related disorders. Clin Genet 2003;64:48-53.
93. Agarwal SK, Lee Burns A, Sukhodolets KE, et al. Molecular pathology of the MEN1 gene. Ann NY Acad Sci 2004;1014:189-198.
94. Raghavan R, Shah S, Kondkar AA, et al. MEN1 935-1G>C splicing mutation in an Indian patient with multiple endocrine neoplasia type 1. Mol Diagn Ther 2007;11:129-131.
95. Lemos MC, Harding B, Shalet SM, Thakker RV. A novel MEN1 intronic mutation associated with multiple endocrine neoplasia type 1. Clin Endocrinol (Oxf) 2007;66:709-713.
96. Drori-Herishanu L, Horvath A, Nesterova M, et al. An Intronic Mutation is Associated with Prolactinoma in a Young Boy, Decreased Penetrance in his Large Family, and Variable Effects on MEN1 mRNA and Protein. Horm Metab Res 2009;41:630-634.
97. Ellard S, Hattersley AT, Brewer CM, Vaidya B. Detection of an MEN1 gene mutation depends on clinical features and supports current referral criteria for diagnostic molecular genetic testing. Clin Endocrinol (Oxf) 2005;62:169-175.
98. Klein RD, Salih S, Bessoni J, Bale AE. Clinical testing for multiple endocrine neoplasia type 1 in a DNA diagnostic laboratory. Genet Med 2005;7:131-138.
99. Odou MF, Cardot-Bauters C, Vantyghem MC, et al. Contribution of genetic analysis in screening for MEN1 among patients with sporadic disease and one or more typical manifestation. Ann Endocrinol (Paris) 2006;67:581-587.
100. Jager AC, Friis-Hansen L, Hansen TV, et al. Characteristics of the Danish families with multiple endocrine neoplasia type 1. Mol Cell Endocrinol 2006;249:123-132.
101. Kishi M, Tsukada T, Shimizu S, et al. A large germline deletion of the MEN1 gene in a family with multiple endocrine neoplasia type 1. Jpn J Cancer Res 1998;89:1-5.
102. Bergman L, Teh B, Cardinal J, et al. Identification of MEN1 gene mutations in families with MEN 1 and related disorders. Br J Cancer 2000;83:1009-1014. (Pubitemid 30780299)
103. Cavaco BM, Domingues R, Bacelar MC, et al. Mutational analysis of Portuguese families with multiple endocrine neoplasia type 1 reveals large germline deletions. Clin Endocrinol (Oxf) 2002;56:465-473.
104. Tham E, Grandell U, Lindgren E, Toss G, Skogseid B, Nordenskjold M. Clinical testing for mutations in the MEN1 gene in Sweden: a report on 200 unrelated cases. J Clin Endocrinol Metab 2008;92:3389-3395.
105. Fukuuchi A, Nagamura Y, Yaguchi H, Ohkura N, Obara T, Tsukada T. A whole MEN1 gene deletion flanked by Alu repeats in a family with multiple endocrine neoplasia type 1. Jpn J Clin Oncol 2006;36:739-744.
106. Marini F, Carbonell Sala S, Falchetti A, Caramelli D, Brandi ML. The genetic ascertainment of multiple endocrine neoplasia type 1 syndrome by ancient DNA analysis. J Endocrinol Invest 2008;31:905-909.
107. Vasen HF, Lamers CB, Lips CJ. Screening for multiple endocrine neoplasia syndrome type I. Arch Int Med 1989;149:2717-2722.
108. Kytola S, Villablanca A, Ebeling T, et al. Founder effect in multiple endocrine neoplasia type 1 (MEN 1) in Finland. J Med Genet 2001;38:185-189.
109. Burgess JR, David R, Greenaway TM, Parameswaran V, Shepherd JJ. Osteoporosis in multiple endocrine neoplasia type 1: severity, clinical significance, relationship to primary hyperparathyroidism, and response to parathyroidectomy. Arch Surg 1999;134:1119-1123.
110. Kouvaraki MA, Shapiro SE, Cote GJ, et al. Management of pancreatic endocrine tumors in multiple endocrine neoplasia type 1. World J Surg 2006;30:643-653.
111. Toledo RA, Lourenco DM, Coutinho FL, et al. Novel MEN1 germline mutations in Brazilian families with multiple endocrine neoplasia type 1. Clin Endocrinol (Oxf) 2007;67:377-384.
112. Lourenco DM Jr, Toledo RA, Coutinho FL, et al. The impact of clinical and genetic screenings on the management of the multiple endocrine neoplasia type 1. Clinics (Sao Paulo) 2007;62:465-476
113. WHO. Technical report series 843. Geneva: World Health Organization, 1994:5-48.
114. Lourenco DM Jr, Toledo RA, Mackowiak II, et al. Multiple endocrine neoplasia type 1 in Brazil: MEN1 founding mutation, clinical features, and bone mineral density profile. Eur J Endocrinol 2008;159:259-274.
115. Falchetti A, Brandi ML. Multiple endocrine neoplasia type I variants and phenocopies: more than a nosological issue? J Clin Endocrinol Metab 2009;94:1518-1520.
116. Pellegata NS, Quintanilla-Martinez L, Siggelkow H, et al. Germ-line mutations in p27Kip1 cause a multiple endocrine neoplasia syndrome in rats and humans. Proc Natl Acad Sci USA 2006;103:15558-15563.
117. Agarwal SK, Mateo CM, Marx SJ. Rare germline mutations in cyclin-dependent kinase inhibitor genes in multiple endocrine neoplasia type 1 and related states. J Clin Endocrinol Metab 2009;94:1826-1834.
118. La P, Desmond A, Hou Z, Silva AC, Schnepp RW, Hua X. Tumor suppressor menin: the essential role of nuclear localization signal domains in coordinating gene expression. Oncogene 2006;25:3537-3546.
119. Tala HP, Carvajal CA, Gonzalez AA, et al. New splicing mutation of MEN1 gene affecting the translocation of menin to the nucleus. J Endocrinol Invest 2006;29:888-893.
120. Sowa H, Kaji H, Hendy GN, et al. Menin is required for bone morphoge-netic protein 2-and transforming growth factor /3-regulated osteoblastic differentiation through interaction with Smads and Runx2. J Biol Chem 2004;279:40267-40275.
121. Sowa H, Kaji H, Kitazawa R, et al. Menin inactivation leads to loss of transforming growth factor beta inhibition of parathyroid cell proliferation and parathyroid hormone secretion. Cancer Res 2004;64:2222-2228.
122. Lacerte A, Lee EH, Reynaud R, et al. Activin inhibits pituitary prolactin expression and cell growth though Smads, Pit-1 and menin. Mol Endocrinol 2004;18:1558-1569.
123. Hendy GN, Kaji H, Sowa H, Lebrun JJ, Canaff L. Menin and TGF-beta superfamily member signaling via the Smad pathway in pituitary, parathyroid and osteoblast. Horm Metab Res 2005;37:375-379.
124. Chen YX, Yan J, Keeshan K, et al. The tumor suppressor menin regulates hematopoiesis and myeloid transformation by influencing Hox gene expression. Proc Natl Acad Sci USA 2006;103:1018-1023.
125. Balogh K, Rácz K, Patócs A, Hunyady L. Menin and its interacting proteins: elucidation of menin function. Trends Endocrinol Metab 2006; 17:357-364.
126. Dreijerink KM, Mulder KW, Winkler GS, Höppener JW, Lips CJ, Timmers HT. Menin links estrogen receptor activation to histone H3K4 trimethyla-tion. Cancer Res 2006;66:4929-4935.
127. MacConaill LE, Hughes CM, Rozenblatt-Rosen O, Nannepaga S, Meyer-son M. Phosphorylation of the menin tumor suppressor protein on serine 543 and serine 583. Mol Cancer Res 2006;4:793-801.
128. Farley SM, Chen G, Guo S, et al. Menin localizes to chromatin through an ATR-CHK1 mediated pathway after UV-induced DNA damage. J Surg Res 2006;133:29-37.
129. Caslini C, Yang Z, El-Osta M, Milne TA, Slany RK, Hess JL. Interaction of MLL amino terminal sequences with menin is required for transformation. Cancer Res 2007;67:7275-7283.
130. La P, Yang Y, Karnik SK, et al. Menin-mediated caspase 8 expression in suppressing multiple endocrine neoplasia type 1. J Biol Chem 2007;282: 31332-31340.
131. Agarwal SK, Impey S, McWeeney S, et al. Distribution of menin-occupied regions in chromatin specifies a broad role of menin in transcriptional regulation. Neoplasia 2007;9:101-107.
132. Theillaumas A, Blanc M, Couderc C, et al. Relation between menin expression and NF-kappaB activity in an intestinal cell line. Mol Cell Endocrinol 2008;291:109-115.
133. Yokoyama A, Cleary ML. Menin critically links MLL proteins with LEDGF on cancer-associated target genes. Cancer Cell 2008;14:36-46.
134. Marek LR, Kottemann MC, Glazer PM, Bale AE. MEN1 and FANCD2 mediate distinct mechanisms of DNA crosslink repair. DNA Repair (Amst) 2008;7:476-486.
135. Bazzi W, Renon M, Vercherat C, et al. MEN1 missense mutations impair sensitization to apoptosis induced by wild-type menin in endocrine pancreatic tumor cells. Gastroenterology 2008;135:1698-1709.
136. Maillard I, Chen YX, Friedman A, et al. Menin regulates the function of hematopoietic stem cells and lymphoid progenitors. Blood 2009;113:1661-1669.
137. Yan J, Yang Y, Zhang H, et al. Menin interacts with IQGAP1 to enhance intercellular adhesion of beta-cells. Oncogene 2009;28:973-982.
138. Milne TA, Dou Y, Martin ME, Brock HW, Roeder RG, Hess JL. MLL associates specifically with a subset of transcriptionally active target genes. Proc Natl Acad Sci USA 2005;102:14765-14770.
139. Karnik SK, Hughes CM, Gu X, et al. Menin regulates pancreatic islet growth by promoting histone methylation and expression of genes encoding p27Kip1 and p18INK4c. Proc Natl Acad Sci USA 2005;102:14659-14664.
140. Scacheri PC, Davis S, Odom DT, et al. Genome-wide analysis of menin binding provides insights into MEN1 tumorigenesis. PLoS Genet 2006;2:e51.
141. Naito J, Kaji H, Sowa H, Hendy GN, Sugimoto T, Chihara K. Menin suppresses osteoblast differentiation by antagonizing the AP-1 factor, JunD. J Biol Chem 2005;280:4785-4791.
142. Bazzi W, Renon M, Vercherat C, et al. MEN1 missense mutations impair sensitization to apoptosis induced by wild-type menin in endocrine pancreatic tumor cells. Gastroenterology 2008;135:1698-1709.
143. Lim LC, Tan MH, Eng C, Teh BT, Rajasoorya RC. Thymic carcinoid in multiple endocrine neoplasia 1: genotype-phenotype correlation and prevention. J Intern Med 2006;259:428-432.
144. Shen HC, He M, Powell A, et al. Recapitulation of pancreatic neuroendo-crine tumors in human multiple endocrine neoplasia type I syndrome via Pdx1-directed inactivation of Men1. Cancer Res 2009;69:1858-1866.
145. Brandi ML, Gagel RF, Angeli A, et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 2001;86:5658-5671.
146. Pieterman CR, Schreinemakers JM, Koppeschaar HP, et al. Multiple endocrine neoplasia type 1 (MEN1): its manifestations and effect of genetic screening on clinical outcome. Clin Endocrinol (Oxf) 2009;70:575-581.
147. McCallum RW, Parameswaran V, Burgess JR. Multiple endocrine neoplasia type 1 (MEN 1) is associated with an increased prevalence of diabetes mellitus and impaired fasting glucose. Clin Endocrinol (Oxf) 2006;65:163-168.
148. Geerdink EA, Van der Luijt RB, Lips CJ. Do patients with multiple endocrine neoplasia syndrome type 1 benefit from periodical screening? Eur J Endocrinol 2003;149:577-582.
149. Machens A, Schaaf L, Karges W, et al. Age-related penetrance of endocrine tumours in multiple endocrine neoplasia type 1 (MEN1): a multicen-tre study of 258 gene carriers. Clin Endocrinol (Oxf) 2007;67:613-622.
150. Lairmore TC, Piersall LD, DeBenedetti MK, et al. Clinical genetic testing and early surgical intervention in patients with multiple endocrine neopla-sia type 1 (MEN 1). Ann Surg 2004;239:637-645.